Isoprenaline/β2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis

• Published in: BMC cancer 2017-12, Vol.17 (1), p.875-875, Article 875
• Main Authors: Lu, Yanjie, Xu, Qian, Zuo, Yanzhen, Liu, Lei, Liu, Shaochen, Chen, Lei, Wang, Kang, Lei, Yuntao, Zhao, Xiangyang, Li, Yuhong
• Format: Article
• Language: English
• Subjects: Angiogenesis; Gastric cancer; Isoprenaline; Plexin-A1; VEGFR2
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-017-3894-0

The role of stress signals in regulating gastric cancer initiation and progression is not quite clear. It is known that stress signals modulate multiple processes such as immune function, cell migration and angiogenesis. However, few studies have investigated the mechanisms of how stress signals contribute to gastric cancer angiogenesis. Here, we used β2-adrenergic receptor (β2-AR) agonist isoprenaline to imitate a stress signal and demonstrated the molecular mechanism underlying stress's influence on tumor angiogenesis. We found that isoprenaline stimulated vascular endothelial growth factor (VEGF) secretion in gastric cancer cells and plexin-A1 expression was induced by human recombinant VEGF165 in both gastric cancer cells and vascular endothelial cells. Furthermore, interfere with plexin-A1 expression in gastric cancer cells influence HUVEC tube formation, migration and tumor growth in vivo. These findings suggest that isoprenaline stimulate VGEF secretion and subsequently up-regulate the expression of plexin-A1 and VEGFR2 in gastric cancer cells, which form a positive impetus to promote tumor angiogenesis. This study reveals a novel molecular mechanism that a stress signal like isoprenaline may enhance angiogenesis via activating plexin-A1/VEGFR2 signaling pathway in gastric cancer, which may be a potential target in development of an anti-angiogenic therapy for gastric cancer.